期刊
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
卷 2013, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2013/946451
关键词
-
资金
- National Science Council [NSC99N024, NSC100-2314-B-040-001, NSC100N446, NSC101N050]
- Taipei Veterans General Hospital [V99ER2-006, VGHUST99-P6-39]
- National Yang-Ming University (Ministry of Education, Aim for the Top University) [99ACT303-2, 100ACT513, 100ACT807, 101ACT513, 102ACTC14]
- MacKay Hospital [Mackay 10187]
- Grape King Inc. in Taiwan [YM99C021, 101J041]
Head and neck squamous cell carcinoma (HNSCC) is a highly lethal cancer. Previously, we identify head and neck cancer initiating cells (HN-CICs), which are highly tumorigenic and resistant to conventional therapy. Therefore, development of drug candidates that effectively target HN-CICs would benefit future head and neck cancer therapy. In this study, we first successfully screened for an active component, named YMGKI-1, from natural products of Antrodia cinnamomea Mycelia (ACM), which can target the stemness properties of HNSCC. Treatment of YMGKI-1 significantly downregulated the aldehyde dehydrogenase (ALDH) activity, one of the characteristics of CIC in HNSCC cells. Additionally, the tumorigenic properties of HNSCC cells were attenuated by YMGKI-1 treatment in vivo. Further, the stemness properties of HN-CICs, which are responsible for the malignancy of HNSCC, were also diminished by YMGKI-1 treatment. Strikingly, YMGKI-1 also effectively suppressed the cell viability of HN-CICs but not normal stem cells. Finally, YMGKI-1 induces the cell death of HN-CICs by dysregulating the exaggerated autophagic signaling pathways. Together, our results indicate that YMGKI-1 successfully lessens stemness properties and tumorigenicity of HN-CICs. These findings provide a new drug candidate from purified components of ACM as an alternative therapy for head and neck cancer in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据